Track topics on Twitter Track topics that are important to you
Tyme Technologies (NASDAQ: TYME) has appointed Jonathan Eckard chief scientific affairs officer. Eckard most recently worked as chief business and strategy officer for cancer drug developer Sellas Life Sciences. New York-based Tyme’s lead drug candidate, SM-88, is in early-stage testing as a potential prostate cancer treatment.
Original Article: Tyme Technologies Taps Eckard for Chief Scientific Affairs PostNEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...